When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Type 2 diabetes in children

Última revisão: 13 Jul 2025
Última atualização: 24 Apr 2025
24 Apr 2025

Dapagliflozin approved by FDA for treatment of type 2 diabetes in children

The sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin has been approved by the Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type 2 diabetes ages 10 years and older. Prior to this, dapagliflozin was approved only in adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control.

The approval in pediatric patients was based on results from T2NOW, one of the largest pediatric type 2 diabetes phase 3 trials to date. Data demonstrated a significant reduction in hemoglobin A1c (HbA1c) for patients treated with dapagliflozin compared with patients receiving placebo.The safety results in this patient population were consistent with those in adults with type 2 diabetes.

Dapagliflozin has also received approval from the European Medicines Agency (EMA) for use in children ages ≥10 years with uncontrolled type 2 diabetes as an adjunct to diet and exercise.

Ver Tratamento: abordagem

Fonte original da atualização

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • polyuria
  • polydipsia
  • acanthosis nigricans
  • nocturia
Detalhes completos

Outros fatores diagnósticos

  • hypertension
  • yeast infections
  • skin infections
  • urinary tract infections
  • fatigue
  • blurred vision
  • weight loss
Detalhes completos

Fatores de risco

  • obesity
  • genetic predisposition/family history
  • African-American, Hispanic, American-Indian, and Asian or Pacific Islander
  • puberty
  • female sex
  • diabetic in-utero environment
  • small for gestational age
  • rapid growth in infancy
  • bottle feeding
  • high protein intake in infancy
  • polycystic ovaries
  • intramyocellular lipid content
  • fat deposition in the liver
  • learning disability
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • urine dipstick
  • random plasma glucose
  • fasting plasma glucose
  • HbA1c
  • autoantibodies to insulin, islet antigen (IA-2), glutamic acid decarboxylase (GAD), and zinc transporter 8 (ZnT8)
Detalhes completos

Investigações a serem consideradas

  • 2-hour plasma glucose
  • random C-peptide
Detalhes completos

Algoritmo de tratamento

AGUDA

ketoacidosis or hyperglycemic hyperosmolar state (HHS)

CONTÍNUA

HbA1c <8.5%: no acidosis or ketosis

HbA1c ≥8.5%: no acidosis with or without ketosis

Colaboradores

Autores

Jennifer Miller, MD
Jennifer Miller

Professor

Department of Pediatrics

University of Florida

Gainesville

FL

Declarações

JM declares that she has received research funding from Soleno Therapeutics, Harmony Biosciences, and Rhythm Pharmaceuticals. JM is an author of a reference cited in this topic.

Chelsea Zimmerman, MD

Clinical Physician

Pediatric Endocrinology

Endocrinology and Metabolism of East Alabama

Opelika

AL

Declarações

CZ declares that she has no competing interests.

Agradecimentos

Dr Jennifer Miller and Dr Chelsea Zimmerman would like to gratefully acknowledge Dr Arlan Rosenbloom and Dr Paul Hiers, previous contributors to this topic.

Declarações

AR is an author of a number of references cited in this topic. Unfortunately, we have since been made aware that AR is deceased. PH declares that he has no competing interests.

Revisores

Philip Zeitler, MD, PhD

Professor of Pediatrics and Clinical Science

University of Colorado School of Medicine

Aurora

CO

Declarações

PZ declares that he has no competing interests.

Julian P. Hamilton-Shield, MB, ChB, MD(Bristol), MRCP, FRCPCH, FRCPCH

Professor

Diabetes and Metabolic Endocrinology

School of Clinical Sciences

University of Bristol

UK

Declarações

In the past, JPHS received speaking honoraria from Sanofi-Aventis, Roche, Abbott, Novo Nordisk, and Nutricia. None of these talks were directly pertinent to the treatment of type 2 diabetes.

Kristen Nadeau, MD

Professor of Pediatric Endocrinology

University of Colorado School of Medicine

Aurora

CO

Declarações

KN declares that she has no competing interests.

Dennis Styne, MD

Professor of Pediatrics

Rumsey Chair of Pediatric Endocrinology

University of California

Sacramento

CA

Declarações

DS declares that he has no competing interests.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

American Diabetes Association. Standards of care in diabetes - 2025. Diabetes care. 2025 Jan;48(suppl 1):S1-352.Texto completo

Shah AS, Barrientos-Pérez M, Chang N, et al. ISPAD clinical practice consensus guidelines 2024: type 2 diabetes in children and adolescents. Horm Res Paediatr. 2024;97(6):555-83.Texto completo  Resumo

Glaser N, Fritsch M, Priyambada L, et al. ISPAD clinical practice consensus guidelines 2022: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes. 2022 Nov;23(7):835-56. Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Type 2 diabetes in children images
  • Diagnósticos diferenciais

    • Impaired glucose tolerance
    • Type 1 diabetes mellitus (T1DM)
    • Monogenic diabetes: maturity-onset diabetes of the young
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Standards of care in diabetes - 2025
    • Type 2 diabetes in children and adolescents​​
    Mais Diretrizes
  • Folhetos informativos para os pacientes

    Diabetes type 2: should I take insulin?

    Diabetes type 2: what treatments work?

    Mais Folhetos informativos para os pacientes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal